CurifyLabs from Helsinki receives EUR2.5M to advance 3D-printing of personalised medicines

CurifyLabs, founded in 2021, was awarded EUR 2.5 million grant by the European Innovation Council (EIC) Accelerator to advance their proprietary MiniLab technology. The solution offers a seamless manufacturing experience to support hospital and community pharmacies in creating personalised medicines.

CurifyLabs was chosen as part of a highly competitive process in which 32 deeptech companies  were selected from 476 applications. The EIC Accelerator supports, in particular, startup companies in developing and scaling up game-changing innovations in the EU.

There’s a large demand  for personalised therapies and our solution aims at helping compounding pharmacists meet those needs.

The grant will help CurifyLabs standardise the process for developing 3D printing compatible pharmaceutical formulations and quality control solutions. This will make MiniLab highly scalable across different therapeutic areas with specific focus on pediatrics and oncology. The solution has already been successfully piloted by several innovative pharmacies in multiple European markets including Finland, Spain, Switzerland, Germany and the Netherlands.

The MiniLab technology automates what has been a largely manual process, allowing for a significant reduction in complexity and time.

“There’s a large and growing demand  for personalised therapies and our solution is aimed at helping compounding pharmacists meet those needs,” says Charlotta Topelius, Founder and CEO at CurifyLabs.

The technology is based on over 10 years of academic research conducted by Prof. Niklas Sandler Topelius. CurifyLabs is a participant in Helsinki’s unique Health Incubator Helsinki programme.